Medpace Holdings, Inc. $MEDP Stock Holdings Lifted by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 44.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 21,942 shares of the company’s stock after acquiring an additional 6,749 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Medpace were worth $13,437,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. AQR Capital Management LLC boosted its position in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the period. Wasatch Advisors LP raised its holdings in Medpace by 14.0% during the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the period. Baillie Gifford & Co. lifted its stake in Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after buying an additional 62,503 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares during the period. Finally, Epoch Investment Partners Inc. increased its position in shares of Medpace by 11.4% in the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after acquiring an additional 45,435 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Down 0.0%

Shares of NASDAQ:MEDP opened at $466.60 on Friday. The firm has a fifty day moving average of $497.26 and a two-hundred day moving average of $537.33. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92. The firm has a market capitalization of $13.24 billion, a P/E ratio of 30.50, a price-to-earnings-growth ratio of 2.24 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. During the same period in the prior year, the business posted $3.67 earnings per share. Medpace’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 20.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on MEDP. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price for the company in a research report on Tuesday, February 10th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Royal Bank Of Canada started coverage on Medpace in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price objective for the company. Finally, Mizuho set a $582.00 price objective on Medpace in a research report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.